Boston, MA 02/12/2014 (wallstreetpr) – Generex Biotechnology Corporation (OTCMKTS:GNBT) is a Toronto-based drug delivery system developer with special focus on systems and technology for delivery of diabetes management drugs. The company strives to offer delivery systems on the commercial level, considering the high incidence of diabetes in the recent decades.
Generex Biotechnology Corporation (OTCMKTS:GNBT) successful development is the exclusive platform, which is uses the technology of delivery of drugs through the use of oral cavity, ensuring there is no deposit on the lungs. The liquid formulations, which the company has since developed, are aimed at delivering the drug through the method of absorption. This is system which the company has developed to ensure drugs are not lost in transit through the conventional and traditional system of drug delivery.
Generex Biotechnology Corporation (OTCMKTS:GNBT) prefers the use of liquid formulations over pellets and other forms used to manage diabetes. The proprietary system offers higher chances of drug delivery over the older formats as the absorption is at a higher rate and is initiated at the oral cavity.
RapidMIst devices through Antigen Express Inc
Generex Biotechnology Corporation (OTCMKTS:GNBT) with its subsidiary- Antigen Express Inc works to deliver the core technology required to deliver through absorption principles. The injection to be administered through the RapidMist, which is Generex Biotechnology Corporation (OTCMKTS:GNBT) owned product. The inner lining of the inner mouth absorbs the drug.
Moves to other disease drug services
Generex Biotechnology Corporation (OTCMKTS:GNBT) also uses the AntigenExpress to deliver immunotherapeutic vaccines, which are used in the treatment of infections, Allergies as well s autoimmune diseases.
In a recent news release the company noted that it has also pioneered Antigen Express for CD4+ T-helper stimulation technology for immunotherapy. It is also possible to modify peptides with Li-Key for other dysfunctions as well. The company has since developed the technologies which will supress li protein of cancer cells, preventing further growth of the cancer cells.
